ASCO 2019 | Radium-223 label change
Bertrand Tombal
Bertrand Tombal, MD, PhD, of the Cliniques Universitaires Saint-Luc, Brussels, Belgium give his opinion on the European Medicines Agency’s (EMA) change to the label for Radium-223 for the treatment of metastatic castration-resistant prostate cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
Related videos
2:43 Targeted screening and risk stratification of prostate cancer - updates from the IMPACT study
Rosalind Eeles
2:36 Erdafitinib and hyperphosphatemia in advanced UrC
Scott Tagawa
3:04 Kidney cancer: minimizing toxicities and hassle in adjuvant therapy
Tim Eisen
3:56 TROPHY-U-01: Initial findings
Scott Tagawa
2:34 Updates on JAVELIN renal 101: primary treatment for patients
Laurence Albiges
